Merck Serono S.A. v. Hopewell Pharma Ventures, Inc.
In the case Merck Serono S.A. v. Hopewell Pharma Ventures, Inc., the Federal Circuit upheld a Patent Trial and Appeal Board decision invalidating claims related to Merck’s multiple sclerosis drug Mavenclad, an oral formulation of the compound Cladribine. Merck Serono S.A. v. Hopewell Pharma Ventures, Inc. – Basic Details: Merck Serono S.A. v. Hopewell Pharma … Read more
